Triple Pill Therapy Lowers Recurrent Stroke Incidence in Patients With Prior Intracerebral Hemorrhage

This multinational randomized controlled trial enrolled 1670 patients with a history of intracerebral hemorrhage. Participants had baseline systolic blood pressure between 130 and 160 mm Hg and were clinically stable. The study setting was multinational, aiming to assess the efficacy of antihypertensive therapy in this specific high-risk population.

The intervention consisted of a triple pill containing telmisartan 20 mg, amlodipine 2.5 mg, and indapamide 1.25 mg administered once daily. The comparator group received a matching placebo. Patients were followed for a median duration of 2.5 years to evaluate long-term outcomes regarding stroke recurrence and cardiovascular safety.

The primary outcome was the first recurrent stroke. In the triple-pill group, 38 patients (4.6%) experienced a recurrent stroke compared to 62 patients (7.4%) in the placebo group. The absolute numbers were 38 out of 833 versus 62 out of 837. The hazard ratio was 0.61 with a 95% confidence interval of 0.41 to 0.92. The p-value was 0.02, indicating statistical significance.

Key secondary outcomes included blood-pressure control and major cardiovascular events. Mean systolic blood pressure was 127 mm Hg in the triple-pill group versus 138 mm Hg in the placebo group. Major cardiovascular events occurred in 6.6% of the triple-pill group compared to 9.8% in the placebo group, with a p-value of 0.04. Death from cardiovascular causes was listed as a secondary outcome but specific rates were not detailed in the provided results.

Safety and tolerability findings indicated a lower rate of serious adverse events in the treatment group. Serious adverse events occurred in 23.2% of the triple-pill group and 26.0% of the placebo group. However, early discontinuation due to adverse event was higher in the triple-pill group at 13.6% compared to 6.0% in the placebo group. An increase of 20% or more in serum creatinine level was the most common adverse event leading to discontinuation. Tolerability was not explicitly reported in the source data.

The study was funded by the National Health and Medical Research Council of Australia and the Brazilian Ministry of Health. Methodological limitations were not explicitly reported in the provided text. The randomized, double-blind, placebo-controlled trial design supports causal inference. The primary outcome was statistically significant with a 95% CI excluding null.

Clinical implications suggest that among patients with intracerebral hemorrhage, treatment with a combination of three low-dose antihypertensive agents in a single pill, in addition to standard care, was associated with a lower incidence of recurrent stroke and major cardiovascular events than placebo. This supports the use of combination therapy for secondary prevention in this population.

Questions remain unanswered regarding long-term safety beyond the median 2.5 years follow-up. The specific impact on death from cardiovascular causes requires further data as rates were not explicitly detailed in the summary results. Clinicians should weigh the reduction in stroke risk against the higher discontinuation rate due to adverse events when considering this regimen.